Animalcare is a leading supplier of generic veterinary medicines and animal identification products to companion animal veterinary markets.

It develops and sells goods and services to veterinary professionals principally for use in companion animals; operating through UK wholesalers and distribution and development partners in key markets in Western Europe.

Its principal product lines are licensed veterinary medicines and companion animal identification products and services.

(AIM:ANCR)

http://www.animalcaregroup.co.uk/

Trading Update & Notice of Results

RNS


RNS Number : 1191E

Animalcare Group PLC

14 July 2016






Animalcare Group plc

("Animalcare" or the "Group")



Trading Update & Notice of Results



Animalcare (AIM: ANCR), a leading supplier of veterinary medicines, provides the following trading update for the year ended 30th June 2016, in advance of releasing its preliminary results on Wednesday 12th October 2016.



Trading Update



The Board is very pleased to report a positive trading performance for the year ended 30th June 2016. Revenues across the Group were up by 8.6% to £14.70m (2015: £13.54m) and underlying operating profits are expected to be broadly in line with last year, exceeding market expectations.



Revenue from sales of the Licensed Veterinary Medicines group was up 7.7% to £9.24m (2015: £8.58m), with growth driven by full year sales of new distribution products launched late in the prior period.



The Companion Animal Identification group revenues increased by 16.0% to £2.68m (2015: £2.31m). Legislation making it compulsory to microchip dogs in the United Kingdom had little effect until the very last minute of its introduction in April 2016. A short-lived but significant increase in sales accounted for most of the increase along with continued strong performance from database services.



Sales from the Animal Welfare Products group improved by 4.9% to £2.78m (2015: £2.65m) driven by our growing infusion accessories range.



In line with one of our stated strategic objectives a dedicated export manager was employed at the start of the financial year and as a result sales to territories outside the UK have grown by 22.8%, ahead of management expectations.



We expect both Underlying Operating Profit and Basic Underlying EPS to be broadly in line with prior year, ahead of market expectations during a period of further strengthening of the core business. The year-end cash position was £7.1m (30th June 2015: £5.8m) with the business continuing to generate strong levels of cash through its investment phase. For the second year, planned investment in our product pipeline has increased significantly on the prior year to circa £1.5m (2015: £0.8m).



Summary and Outlook



During the full year Animalcare re-launched its market leading intravenous fluids with a new European contract manufacturer allowing the range to be extended, product presentation and margin to be improved. We are planning the launch of several new products in the new financial year, some on distribution and others from our own in-house development pipeline.



It is expected that the compulsory microchipping legislation for dogs in the UK will result in a decline in the available dog market. However, Animalcare has plans to evolve the established business model to build upon the anticipated lower revenue levels.



The product development pipeline is progressing well; investment has increased 8-fold in the space of two years and is already producing returns.



The result of the EU referendum has introduced some uncertainty in the UK economy and in particular sterling weakness which the Group will continue to monitor. This will impact the cost of a large proportion of our pharmaceutical products imported from mainland Europe, denominated in Euros, and microchips supplied in USD. However this is balanced in part by the increasing level of Euro-denominated sales outside the UK and in the short-term, our hedging position.



Notwithstanding the above, the Group has a strong balance sheet and our long-term business plans are unchanged and being actively pursued without delay.



Following the strong trading performance in the year, particularly from the Licensed Veterinary Medicines group, the Board remains confident about the prospects for the new financial year and is pleased with the momentum of the product development pipeline and the new UK distribution opportunities the company has attracted. In addition, export opportunities will have increasing significance on the success of the business in the coming two to three years.



This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

Broker Forecast - Panmure Gordon issues a broker note on Animalcare Group PLC

Panmure Gordon today reaffirms its buy investment rating on Animalcare Group PLC (LON:ANCR) and raised its price target to 337p (from 245p). Story provided by StockMarketWire.com

New high.

Final Results
RNS
RNS Number : 2795M
Animalcare Group PLC
12 October 2016
 
 
 
Animalcare Group plc
("Animalcare", the "Company" or the "Group")
 
Final Results
 
Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, announces results for the year ended 30th June 2016. Animalcare has performed well this year particularly during the second half of the year and has built a strong and scalable platform continuing the Company's record of consistent growth and maintaining a progressive dividend policy.
 
Animalcare is made up of three product groups: Licensed Veterinary Medicines, Companion Animal Identification and Animal Welfare Products.
 
Financial Highlights
·     Revenue up 8.6% to £14.7m (2015: £13.5m)
·     Underlying* operating profit up 2.6% to £3.2m (2015: £3.1m)    
·     Underlying* basic earnings per share up 3.2% to 13.0p (2015: 12.6p)
·     Reported pre-tax profits up 2.5% to £3.09m (2015: £3.01m)
·     Strong, debt free balance sheet with net cash of £7.1m (2015: £5.8m)
·     Cash generated from operations £4.6m (2015: £4.5m)
·     Total recommended dividend up 6.6% to 6.5p (2015: 6.1p)
 
*underlying measures are before the effect of exceptional costs and other items
 
Operational Highlights
·     Robust increase in sales of Licensed Veterinary Medicines, up 7.7% to £9.2m (2015: £8.6m)
·     Revenue increase in the Companion Animal Identification Group, up 16.1% to £2.7m (2015: £2.3m) including an incremental benefit of £0.3m following the law making it compulsory for dogs to be microchipped in England, Scotland and Wales
·     Revenues from the Animal Welfare Products range increased 5.1% to £2.78m (2015: £2.65m)
·     Strong momentum in building value within our product development pipeline with planned investment increasing by 100% to £1.6m
 
Iain Menneer, Chief Executive Officer of Animalcare, said: "I am pleased with the progress we have made this year. The Group is currently in a strong position and generating significant cash flows. We will use this to invest in the business and are now in a good position to step up our investment in products and wider opportunities to provide the long-term success of the business. We are well placed as a Group to deliver further growth in the year to come and committed to return shareholder value." 

20 shares for the future

Trading update & Notice of Interim Results
RNS
RNS Number : 5900T
Animalcare Group PLC
09 January 2017
 
 
Animalcare Group plc
(the 'Group' or the 'Company')
 
Trading update & Notice of Interim Results
 
Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines,  provides a trading update for the first six months of the current financial year ahead of publishing its interim results on 15th February 2017. Following a very strong first half-year for the Group, the Board is pleased to announce that it expects that trading for the year ending 30th June 2017 will be ahead of current market expectations.
 
Trading Update
 
Trading during the period has been ahead of the Board's expectations in both sales and profit terms, which saw revenue growth of 12.0% versus the same period last year to £7.97m (2015: £7.11m).
 
The Licensed Veterinary Medicines group continued to grow strongly in the first half with revenues increasing 17.2% to £5.37m (2015: £4.58m), driven by growth in the UK of 14.6% and outside the UK of 37.7%. Sales from new products launched in the period contributed around £0.20m, or 4%, of the overall 17.2% growth. Gross margins have improved versus the prior year through a combination of favourable sales mix and cost of goods initiatives.
 
Sales from the Animal Welfare Products group improved by 13.4% to £1.51m (2016: £1.34m) driven by continued strong growth of our infusion accessories range.
 
The Companion Animal Identification group revenues decreased by 9.2% to £1.09m (2016: £1.20m). Following the implementation of compulsory microchipping of dogs in the United Kingdom in April 2016, we expected and have observed a reduction in microchip volumes, which we expect to last into the medium-term. Database services however have continued to grow.
 
 The Group's cash position remains strong with period end cash balances at approximately £7.0m (30th June 2016: £7.1m, 31st December 2015: £6.1m). As expected, we have made a significant net investment in working capital to support growth.
 
Summary and Outlook
 
Four products were launched in the first half; three as part of a range of ear cleaners and treatments, all on distribution, and one new product from our in-house development pipeline, Acecare (a companion animal sedative).
 
It is expected that there will be two further product launches in H2, both on distribution from EU partners and both for use with companion animals.
 
As we highlighted in our FY16 results in October, despite the uncertainty of Brexit, the Board took the decision to accelerate investment in new products on the strength of continued positive trading momentum and the Group's strong financial position. We are pleased to report good progress in our product development pipeline, in particular with regard to the identification of novel formulations which, as previously stated, are strategic focus for the Group. We expect expenditure on our pipeline to increase for the current financial year to around £2.0m (FY16: £1.6m).
 
Following a very strong first half-year for the Group, the Board is pleased to announce that for the year ending 30th June 2017 it expects trading will be ahead of current market expectations and revenues to be in line with the first half.

Half year report

Highlights
·    Strong revenue growth from our Licensed Veterinary Medicines group, up 17.2% to £5.37m (2015: £4.58m) driven by strong domestic and export like-for-like growth of 13.0%, and 4.2% contribution from sales of four new products launched in the period.
·    Revenues from the Animal Welfare Products range increased 13.3% to £1.51m (2015: £1.34m).
·    Continued focus on our export business started delivering significant commercial benefit with revenues up 37.7% versus prior period.
·    Momentum in our product development pipeline continues with expenditure in the period of £0.6m and anticipated full year investment increasing to £2.0m (FY16: £1.6m).

15 Feb
Panmure Gordon
385.00
Buy

Animalcare Group PLC (ANCR:LSE) set a new 52-week high during today's trading session when it reached 355.00. Over this period, the share price is up 73.17%.

i thought this was going to be a dog of a share. Obviously I should have vetted it's progress! :o)

Going in to orbit. :-))

Without a paws! ;o)

paw joke. :-))

Yeah, a bit ruff! :o)

Animalcare Group PLC (ANCR:LSE) set a new 52-week high during today's trading session when it reached 460.00. Over this period, the share price is up 96.51%.
52-week range
Today